Figure 2 | Scientific Reports

Figure 2

From: Imaging endogenous macrophage iron deposits reveals a metabolic biomarker of polarized tumor macrophage infiltration and response to CSF1R breast cancer immunotherapy

Figure 2The alternative text for this image may have been generated using AI.

Validation of CSF1R immunotherapy effects on tumor growth and TAM accumulation in PyMT-MMTV breast cancer models. (a) Murine breast tumor models were established by orthotopic mammary fat pad injections and measured by caliper in TS1 and 99LN models during administration of the CSF1R inhibitor BLZ945 (200 mg/kg). Arrows indicate start of BLZ945 treatment (mean ± s.e.m. n = 5 mice/group, ***p < 0.001, ****p < 0.0001, 2-way ANOVA with Tukey’s multiple comparison test). Representative first-echo images from MGE MRI experiments made at study endpoints in control and BLZ945 treated (b,c) TS1 and (d,e) 99LN MMTV-PyMT models. (f) Pre-treatment and endpoint tumor volumes measured by MRI in the CSF1R inhibitor trials. (mean + s.e.m., n = 8 mice/group, **p < 0.01, two-tailed unpaired students t-test). Flow cytometry panels of TAMs (live CD45+Ly6c−Ly6g− cells gated on CD11b+F4/80+ cells) obtained from control and BLZ945 treated (g,h) TS1, and (i,j) 99LN tumors. (k) TAM frequency with respect to total CD45+ myeloid cells in the TS1 and 99LN CSF1R inhibitor trials (mean + s.e.m. n = 4 mice/group, **p < 0.01, ***P < 0.001, two-tailed unpaired students t-test).

Back to article page